Professor Jimmy Limdi caught up with Dr Bram Verstockt, co-author of the VIPER survey presented at UEG Week 2021, to discuss how resources for inflammatory bowel disease care and education differs across Europe.
Professor Ailsa Hart talks with Professor Arie Levine, the lead author of the CRAFT UC trial presented at the ECCO 2021 Congress, to discuss the trial and its potential implications for inflammatory bowel disease treatment in greater detail.
In this article, we explore World IBD Day and consider why it is so important to effectively discuss and address the impact of inflammatory bowel disease on patient quality of life.
Leading inflammatory bowel disease Clinical Nurse Specialists, Aileen Fraser and Kay Greveson, discuss the importance of World IBD Day and provide their insights on the challenges patients with IBD face in their everyday lives.
Professor Charlie Lees reflects on the recent growth of telemedicine in inflammatory bowel disease care.
Dr Alexa Duff discusses emotional detection and behavioural regulation systems, and how understanding these systems can help patients with inflammatory bowel disease to make and accept changes in their lives.
Dr Alexa Duff discusses how healthcare professionals can use behavioural regulation systems in clinical practice to assist patients with inflammatory bowel disease in making changes.
UK-IBD-FIL-202203-00030 | Date of preparation: October 2023
Adverse events should be reported.
For Great Britain, reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (download from the Apple App Store or Google Play Store).
Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@glpg.com or 0800 072 7878.
Adverse events should be reported.
For Northern Ireland, reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (download from the Apple App Store or Google Play Store).
Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@glpg.com or 0800 072 7878.
Adverse events should be reported.
For the Republic of Ireland, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971.
Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@glpg.com or 00800 7878 1345.
Galapagos and the Galapagos logo are registered trademarks of Galapagos NV.
© 2022 Galapagos NV. All rights reserved.
GB-IBD-FIL-202208-00005 |
Date of preparation: October 2023
Contact Us
Galapagos Biotech Ltd
148 Belmont Rd, Uxbridge UB8 1QS
medicalinfo@glpg.com
Contact Us
Galapagos Biotech Ltd
148 Belmont Rd, Uxbridge UB8 1QS
medicalinfo@glpg.com
© Copyright 2021 Galapagos NV
This link will take you away from the Galapagos website and you will be re-directed to a non-Galapagos website. Galapagos does not accept liability for sites controlled by third-parties.
*By choosing the "Healthcare Professional" option, you affirm your status as a healthcare professional in the UK and Ireland and acknowledge that you will receive promotional information pertaining to prescription-only medicines.